

S2 Table. Median overall survival with 95% confidence intervals in months according to subgroups

Subgroup	2005-2008 (group I)	2009-2011 (group II)	2012-2014 (group III)	p-value ^{a)}
All patients	15.6 (11.0-21.0)	17.9 (15.0-23.4)	15.0 (13.9-18.2)	NS
HR+/HER2–	24.2 (11.5-NA)	19.5 (11.7-60.1)	17.2 (14.3-23.1)	NS
HER2+	21.0 (14.8-28.6)	20.8 (15.3-32.7)	18.2 (14.6-30.8)	NS
Triple-negative	9.8 (4.8-15.6)	15.0 (8.1-23.4)	9.7 (7.5-12.6)	NS
Initial stage I-II	16.7 (10.2-27.0)	21.0 (11.2-31.9)	15.0 (12.2-20.9)	NS
Initial stage III-IV	14.0 (9.8-22.9)	17.9 (14.9-23.4)	15.0 (13.6-21.1)	NS
No. of BM ≤ 4	21.4 (16.7-31.8)	21.0 (15.3-29.5)	20.9 (16.4-27.2)	NS
No. of BM > 4	6.8 (4.2-16.9)	13.5 (10.9-26.3)	11.0 (8.3-14.6)	0.05
Breast-GPA 0-1.0	2.9 (1.7-NA)	15.3 (5.5-NA)	8.0 (3.6-12.6)	NS
Breast-GPA 1.5-2.0	11.0 (6.8-19.2)	10.4 (7.3-19.9)	10.5 (7.7-12.9)	NS
Breast-GPA 2.5-3.0	25.2 (16.9-34.3)	20.8 (15.3-32.0)	19.5 (16.5-27.9)	NS
Breast-GPA 3.5-4.0	15.5 (12.8-NA)	29.5 (14.9-55.4)	30.0 (17.8-NA)	0.03
WBRT alone	10.1 (5.5-18.3)	12.4 (10.0-18.5)	12.6 (10.9-17.3)	NS
SRS/FSRT alone	14.1 (9.8-34.7)	31.9 (17.9-41.1)	16.5 (13.7-23.3)	0.05

BM, brain metastasis; Breast-GPA, breast cancer-specific graded prognostic assessment; FSRT, fractionated stereotactic radiotherapy; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; NA, not available; NS, not significant; SRS, stereotactic radiosurgery; WBRT, whole-brain radiotherapy. ^{a)}p-value by log-rank test.